K Ryggen

Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial

Kristin Kaasen Jørgensen, Inge Christoffer Olsen, Guro Løvik Goll et al. · The Lancet · 2017 · 789 citations

Oncology, Clinical Translation, Originator Infliximab +10

Photothermally Induced Vessel-Wall Necrosis After Pulsed Dye Laser Treatment: Lack of Response in Port-Wine Stains With Small Sized or Deeply Located Vessels

Eli Janne Fiskerstrand, Lars O. Svaasand, G. Kopstad et al. · Journal of Investigative Dermatology · 1996 · 136 citations · Full text

Dye Laser Treatment, Laser Applications, Port-wine Stains +2

Long‐term efficacy and safety of biosimilar infliximab (CT‐P13) after switching from originator infliximab: open‐label extension of the NOR‐SWITCH trial

Guro Løvik Goll, Kristin Kaasen Jørgensen, J. Sexton et al. · Journal of Internal Medicine · 2019 · 116 citations · Full text

Clinical effects of dynamic cooling during pulsed laser treatment of port-wine stains

E. J. Fiskerstran, K Ryggen, L. T. Norvang et al. · Lasers in Medical Science · 1997 · 21 citations

Laser Optics, Advanced Laser Processing, Engineering +5

Extracorporeal photochemotherapy in patients with cutaneous T‐cell lymphoma: is clinical response predictable?

Vidar Rao, K Ryggen, M Aarhaug et al. · Journal of the European Academy of Dermatology and Venereology · 2006 · 16 citations